Scientist profiles G-L

Administrative Assistant: Debbie Posner
Phone: 416-480-4951
Email: Debbie.Posner@sunnybrook.ca

Education:

• B.Sc., 2004, biology, Western University, Canada
• MD, 2008, Western University, Canada
• M.Sc., 2015, epidemiology, Harvard University, U.S.
• PhD, 2016, stereotactic ablative radiotherapy for lung cancer, Vrije Universiteit Amsterdam, Netherlands

Appointments and Affiliations:

• Scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
• Radiation oncologist, Sunnybrook Health Sciences Centre
• Associate professor, department of radiation oncology, University of Toronto

Research Foci:

• Lung cancer
• Kidney cancer
• Oligometastases
• Stereotactic radiotherapy
• Health economics

Research Summary:

Dr. Louie’s academic focus is the use of comparative effectiveness research in lung, kidney and oligometastatic cancers. He has expertise in clinical trials, patient-reported outcomes, population databases, decision analyses, health economics and technological appraisals.

Selected Publications:

See current publications list at PubMed.

1. Siva S, Louie AV, Warner A, Muacevic A, Gandhidasan S, Ponsky L, Ellis R, Kaplan I, Mahadevan A, Chu W, Swaminath A, Onishi H, Teh B, Correa RJ, Lo SS, Staehler M. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer. 2018 Mar 1;124(5):934–42.
2. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF, Roth JA. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015 Jun;16(6):630–7.
3. Louie AV, Palma DA, Dahele M, Rodrigues GB, Senan S. Management of early-stage non-small-cell lung cancer using stereotactic ablative radiotherapy: controversies, insights and changing horizons. Radiother Oncol. 2015 Feb;114(2):138–47.
4. Louie AV, Senan S, Patel P, Ferket BS, Lagerwaard FJ, Rodrigues GB, Salama JK, Kelsey C, Palma DA, Hunink MG. When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer? A decision analysis. Chest. 2014 Oct;146(4):1021–28.
5. Louie AV, Senthi S, Palma DA. Surgery versus SABR for NSCLC. Lancet Oncol. 2013 Nov;14(12):e491.

Related News and Stories:

• Research into cancer technologies and services recognized with funding: Six Sunnybrook Research Institute scientists working in prevention, screening and care receive support from provincial network (June 4, 2019)
• International Radiosurgery Oncology Consortium for Kidney group: Stereotactic ablative radiotherapy for renal cell carcinoma in patients with one kidney, The American Society of Clinical Oncology Post (Oct. 30, 2018)
• New radiation technique could improve quality of life in lung cancer patients, Medical Xpress (Jan. 29, 2018)
• Role of stereotactic ablative radiotherapy in early-stage lung cancer, Cancer Network (May 24, 2017)
• Some doctors not reporting unfit drivers to Ontario, CBC News (June 5, 2012)

Related Links:

• Canadian Pulmonary Radiotherapy Investigators Group
• Research Gate profile
• U of T profile